REPL Replimune Group, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
15:58
Aug 27
Aug 27
Author added to VERA and BHVN on weakness citing FDA flexibility and narrative shift.
Author added to VERA and BHVN on weakness citing FDA flexibility and narrative shift, while giving secondary looks to REPL, CAPR, and QURE without explicit positions.
LOW
17:39
Aug 23
Aug 23
Author argues IOVA is overvalued at $4B with unsustainable losses.
Author argues IOVA is overvalued at $4B with unsustainable losses, imminent competition from MRNA/MRK and REPL, and recent rally driven by unrelated short squeezes, making it a clear downside call.
00:22
Aug 21
Aug 21
The author notes REPL traded down after data release.
The author notes REPL traded down after data release, a factual price observation without a directional position or forecast.
LOW
20:04
Aug 13
Aug 13
Author complains their short book is underperforming while longs dominate.
Author complains their short book is underperforming while longs dominate, listing prior short candidates as context rather than fresh trade calls.
10:47
Aug 12
Aug 12
Author lists seven short-selling opportunities with specific bearish catalysts like competition.
Author lists seven short-selling opportunities with specific bearish catalysts like competition and overvaluation, signaling a clear short thesis on each.
02:10
Aug 07
Aug 07
US regulators approved Replimune's melanoma drug for patients who failed immune therapy.
US regulators approved Replimune's melanoma drug for patients who failed immune therapy, marking a major victory after two prior FDA rejections.
20:02
Aug 06
Aug 06
REPL approved for advanced melanoma
Reports REPL approval with a broad label for advanced melanoma; regulatory milestone, no directional opinion stated.
LOW
13:06
Aug 04
Aug 04
Wall Street analysts issued a broad batch of upgrades, downgrades.
Wall Street analysts issued a broad batch of upgrades, downgrades, and coverage initiations across multiple stocks, with notable price target changes including NKE cut to $40 and REPL raised to $17.
12:39
Jul 31
Jul 31
US pre-market movers show Apple falling on weak China sales and guidance.
US pre-market movers show Apple falling on weak China sales and guidance, Amazon rising on faster AWS growth, with mixed earnings across energy, healthcare, and tech stocks.
12:35
Jun 30
Jun 30
Premarket movers report shows AeroVironment soaring 30% on strong results.
Premarket movers report shows AeroVironment soaring 30% on strong results, Aevex climbing on a contract win, Block upgraded by Piper Sandler, Concentrix tumbling on a lowered outlook, and Replimune gaining on an analyst upgrade.
11:42
May 29
May 29
The author exited a scalp trade in REPL at $7.2, referencing a prior FDA-related context.
The author exited a scalp trade in REPL at $7.2, referencing a prior FDA-related context, without expressing a forward directional view.
LOW
11:37
May 29
May 29
Author re-enters $REPL long, citing a shift in FDA direction after key personnel exits.
Author re-enters $REPL long, citing a shift in FDA direction after key personnel exits as catalyst for improved regulatory outlook.
MED
15:46
Apr 13
Apr 13
Replimune's drug has strong efficacy and support.
The FDA rejection of Replimune's melanoma drug was unfair because the drug has strong efficacy data with a 34% remission rate and durable responses, it resensitizes patients to anti-PD-1 therapy, and has broad support from oncologists and patient advocacy groups, indicating that the drug should be approved and the company has promising prospects.
HIGH
About REPL Analyst Coverage
Buzzberg tracks REPL (Replimune Group, Inc.) across 7 sources. 2 bullish vs 0 bearish calls from 7 analysts. Sentiment: predominantly bullish (15%). 13 total trade ideas tracked. Latest voices: seedy19tron, A May MD, Bloomberg.